STOCK TITAN

Oppenheimer Expands Institutional Derivatives Platform with Senior Team Additions

(Neutral)
(Neutral)
Tags

Oppenheimer Holdings (NYSE: OPY) is expanding its Institutional Derivatives business by adding seven senior professionals from Guggenheim Securities across derivatives strategy, sales, trading and technology. New team members include Ed Boll as Head of Derivatives Strategy, plus specialists in sales, trading and algo technology.

The hires bring institutional relationships with hedge funds and asset managers and expertise in areas such as convertible and capital-structure strategies, volatility and credit arbitrage, biotech and healthcare derivatives, AI infrastructure, high-performance computing and crypto-related equities. According to Oppenheimer, the enlarged team will collaborate closely with its Convertible Bonds, High Yield, cash equities and prime services units to support the full institutional derivatives lifecycle from idea generation through structuring, execution and technology.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction – OPY

-0.84%
-0.84% News Effect

On the day this news was published, OPY declined 0.84%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

April 9's leadership appointment and March 31 platform expansion were followed by 2.89% and 1.86%, r...
Analysis

April 9's leadership appointment and March 31 platform expansion were followed by 2.89% and 1.86%, respectively. Those precedents frame this derivatives hiring announcement, while its operational contribution and financial effect remain unquantified.

Key Figures

Senior professionals added: seven senior professionals
1 metrics
Senior professionals added seven senior professionals Institutional Derivatives business expansion

Historical Context

5 past events · Latest: May 01 (Negative)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
May 01 First-quarter earnings Negative -6.7% Reported first-quarter loss and legal accrual preceded the stock's negative 24-hour reaction.
Apr 24 Litigation settlement Positive +5.5% Settled cash-sweep litigation for $70 million, but shares posted a positive reaction.
Apr 09 Leadership appointment Positive +2.9% Elevated David Fleming and named Ron Guidi to Private Client leadership roles.
Apr 08 Leadership appointment Positive +5.6% Named Bill Farmer to lead aerospace and defense technology investment banking.
Mar 31 Platform expansion Positive +1.9% Added three managing directors to expand municipal capital markets underwriting and trading.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Platform and leadership expansion announcements aligned with positive reactions, while the earnings release aligned with a negative reaction.

Key Terms

derivatives, convertible securities, capital-structure strategies, prime services
4 terms
derivatives financial
"expansion of its Institutional Derivatives business"
Derivatives are financial contracts whose value depends on the price or performance of another asset, such as a stock, bond, commodity, currency or interest rate. Investors use them to hedge against risk, to speculate on future price moves, or to gain exposure without owning the asset — like buying insurance or placing a leveraged bet — so they can both protect portfolios and magnify gains or losses, affecting risk and market liquidity.
View in glossary
convertible securities financial
"experience in convertible securities, strategy development and idea generation"
Convertible securities are bonds or preferred shares that can be exchanged for a company’s common stock at a predetermined price or under specified conditions. They matter because they combine the steadiness of a loan or fixed dividend with the potential upside of ownership; like a safety‑net that carries a one‑time ticket to become a shareholder, they affect expected returns and can dilute existing stock if converted.
View in glossary
capital-structure strategies financial
"specialized knowledge across convertible and capital-structure strategies"
A set of decisions a company makes about how to fund itself and return money to owners, including the mix of debt and equity, timing of borrowing or repayment, dividend and share buyback policies, and refinancing choices. These choices shape the company’s risk profile, borrowing costs, and financial flexibility—like adjusting the balance between a mortgage and savings in a household budget, they influence how much returns and volatility investors can expect.
prime services financial
"including Convertible Bonds, High Yield, cash equities and prime services"
A bundle of specialized brokerage and support services that large banks or broker-dealers offer to professional investors such as hedge funds and institutional traders, including trade execution, custody and clearing, financing and margin, securities lending, and consolidated reporting. Think of it like a full-service backstage team that handles financing, record-keeping and access to markets so sophisticated traders can operate at scale; its strength and terms affect liquidity, leverage, counterparty exposure and operational efficiency that matter to market participants and shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

New capabilities broaden sector and product expertise while strengthening strategy, execution and collaboration across Oppenheimer's Institutional Equities platform

NEW YORK, July 20, 2026 /PRNewswire/ -- Oppenheimer & Co. Inc. (Oppenheimer), a leading investment bank, wealth manager and subsidiary of Oppenheimer Holdings Inc. (NYSE: OPY), today announced the expansion of its Institutional Derivatives business with the addition of seven senior professionals across derivatives strategy, sales, trading and technology.

The team, which joins from Guggenheim Securities, includes Ed Boll, Head of Derivatives Strategy; Steve Ahn, Derivatives Strategy and Idea Generation; Matthew Shaffer, Derivatives Sales and Trading; Steven Weingroff, Derivatives Sales; Nick Colucci, Derivatives Sales; Julia Marcus, Derivatives Sales; and Jia Li, Derivatives Algo Technology. William Visconto will also support the business in an external advisory capacity.

"This expansion represents an important investment in the continued development of our Institutional Equities platform," said John Hellier, Senior Managing Director and Head of Equities at Oppenheimer. "The team adds experienced professionals, established institutional relationships and specialized expertise across strategy, sales, trading and technology. Those capabilities will allow us to provide more comprehensive support to clients while creating stronger connections across our broader equities franchise."

The team brings relationships across hedge funds, asset managers and other institutional investors, as well as experience supporting both high-touch and low-touch options execution. Its members also add specialized knowledge across convertible and capital-structure strategies, macro and systematic risk management, volatility and credit arbitrage, event-driven investing and several of the market's most actively traded sectors.

Mr. Weingroff has extensive experience covering institutional clients across AI infrastructure, high-performance computing and crypto-related equities, along with capital-structure and convertible-arbitrage strategies. Mr. Colucci brings established expertise in biotech and healthcare derivatives, with a focus on catalyst- and event-driven trading around clinical data, regulatory decisions and broader sector themes. Mr. Ahn adds experience in convertible securities, strategy development and idea generation.

The expanded team will work closely with complementary businesses across Oppenheimer, including Convertible Bonds, High Yield, cash equities and prime services. That collaboration is expected to broaden client coverage, generate more cross-product dialogue and provide institutional investors with more coordinated access to the firm's sector, product and execution capabilities.

"We are building a derivatives franchise that combines market insight, specialized expertise and responsive execution," said Alon Rosin, Head of Institutional Derivatives Sales and Trading at Oppenheimer. "Ed and the team strengthen our ability to engage clients from the earliest stages of idea generation through structuring and execution. Just as importantly, their arrival gives us more ways to connect our derivatives capabilities with the expertise that already exists across the firm."

With the addition of this team, Oppenheimer grows coverage across the institutional derivatives lifecycle—from strategy development and idea generation to structuring, execution and technology—while adding senior coverage and specialization across a range of product areas and market sectors. This increases the firm's capacity to originate and execute customized solutions involving volatility management, portfolio construction and hedging, liquidity, risk arbitrage and other complex investment objectives. The result is broader, more frequent institutional client engagement, with conversations shifting beyond transactional execution toward longer-term strategic collaboration on risk management and portfolio strategy.

For Oppenheimer, the investment is part of a broader effort to develop a more connected Institutional Equities platform around areas where experienced professionals, technical expertise and close client relationships remain important sources of differentiation. The expanded derivatives business gives clients access to a wider range of ideas and capabilities while positioning Oppenheimer to pursue additional opportunities across products, sectors and investment strategies.

About Oppenheimer Holdings Inc.

Oppenheimer Holdings Inc., through its Oppenheimer & Co. Inc. subsidiary and related entities, provides a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, businesses and institutions. For more information, please visit www.oppenheimer.com.

Media Contact:
Michael Dugan
Haven Tower Group LLC
424 317 4852
mdugan@haventower.com

Cision View original content:https://www.prnewswire.com/news-releases/oppenheimer-expands-institutional-derivatives-platform-with-senior-team-additions-302828982.html

SOURCE Oppenheimer & Co. Inc.

FAQ

What did Oppenheimer (NYSE: OPY) announce about its Institutional Derivatives platform on July 20, 2026?

Oppenheimer announced it expanded its Institutional Derivatives business by adding seven senior professionals from Guggenheim Securities. According to Oppenheimer, the new team enhances strategy, sales, trading and technology capabilities and is intended to support institutional clients across the full derivatives lifecycle.

Who are the key senior hires joining Oppenheimer’s Institutional Derivatives team from Guggenheim Securities?

The expanded team includes Ed Boll as Head of Derivatives Strategy, plus Steve Ahn, Matthew Shaffer, Steven Weingroff, Nick Colucci, Julia Marcus and Jia Li. According to Oppenheimer, these professionals cover derivatives strategy, sales, trading and derivatives algo technology for institutional clients.

How will Oppenheimer’s new derivatives team strengthen its Institutional Equities platform for OPY investors?

The new team is expected to broaden sector and product expertise and deepen institutional relationships. According to Oppenheimer, the hires support more comprehensive client coverage, cross-product dialogue and coordinated access to derivatives, convertible bonds, high yield, cash equities and prime services capabilities.

What sectors and strategies will Oppenheimer’s expanded derivatives team focus on?

According to Oppenheimer, the team brings expertise in AI infrastructure, high-performance computing, crypto-related equities, biotech and healthcare derivatives, as well as convertible and capital-structure strategies, macro and systematic risk management, volatility and credit arbitrage, and event-driven investing across actively traded sectors.

How does the Oppenheimer derivatives expansion affect support for biotech and healthcare trading?

Oppenheimer reports that Nick Colucci adds specialized expertise in biotech and healthcare derivatives. According to Oppenheimer, this includes catalyst- and event-driven trading around clinical data releases, regulatory decisions and broader sector themes, enhancing service to institutional investors active in healthcare-related options.

How will Oppenheimer’s new Institutional Derivatives team collaborate with other OPY business units?

According to Oppenheimer, the expanded derivatives team will work closely with Convertible Bonds, High Yield, cash equities and prime services. This collaboration is expected to expand client coverage, generate more cross-product dialogue and support customized solutions for risk management and portfolio strategy.